comparemela.com

Latest Breaking News On - Kevin charles gorman - Page 1 : comparemela.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Q2 2024 Earnings of $1.11 Per Share

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Q2 2024 Earnings of $1.11 Per Share
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Neurocrine-bioscience
William-blair
Kevin-charles-gorman
Davidw-boyer
First-horizon-advisors-inc
Commonwealth-equity-services
Nasdaq
Quadrant-capital-group
Securities-exchange-commission
Envestnet-portfolio-solutions-inc

Certuity LLC Invests $415,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 3,150 shares of the company’s stock, valued at approximately $415,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Headinvest LLC purchased a new stake […]

United-states
Neurocrine-biosciences
Kevin-charles-gorman
Eric-benevich
Nasdaq
Bluepath-capital-management
Fifth-third-bancorp
Wells-fargo-company
Third-bancorp
Barclays
Lindbrook-capital
Neurocrine-biosciences-inc

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $138.00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $138.00 at BMO Capital Markets
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Los-angeles
California
Neurocrine-biosciences
Kevin-charles-gorman
Ingrid-delaet
Capital-partners
Jpmorgan-chase-co
Vanguard-group-inc
Goldman-sachs-group
Los-angeles-capital-management
Brown-advisory-inc

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $164.00 by Analysts at Canaccord Genuity Group

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price hoisted by research analysts at Canaccord Genuity Group from $154.00 to $164.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 17.29% from […]

United-states
Ingrid-delaet
Neurocrine-biosciences
Kevin-charles-gorman
Canaccord-genuity-group
Edgerock-capital
Barclays
Jpmorgan-chase-co
Neurocrine-biosciences-inc
Mather-group
Lindbrook-capital
Benjaminf-edwards-company-inc

Russell Investments Group Ltd. Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Russell Investments Group Ltd. Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Kevin-charles-gorman
Matt-abernethy
Barclays
Capital-partners
Securities-exchange-commission
Charles-schwab-investment-management-inc
Cantor-fitzgerald
Citigroup
Neurocrine-biosciences-company-profile
Westfield-capital-management-co

vimarsana © 2020. All Rights Reserved.